Table 4. Diagnostic performance of anti-BIRC5 autoantibody in different subgroups of evaluation phase.

	AUC (95% CI)	P	Se (%) (95% CI)	Sp (%) (95% CI)	PPV (%)	NPV (%)	Accuracy (%)
AFP
APHCC (n = 149)	0.718 [0.668–0.769]	<0.0001	28.2 [21.6–35.9]	89.8 [85.3–93.0]	62.7	67.2	66.4
ANHCC (n = 95)	0.738 [0.681–0.795]	<0.0001	34.7 [25.9–44.7]	89.8 [85.3–93.0]	56.9	78.0	74.3
TNM stage, n (%)
I + II (n = 98)	0.743 [0.687–0.80]	<0.0001	35.7 [26.9–45.6]	89.8 [85.3–93.0]	58.3	77.7	74.3
III + IV (n = 92)	0.718 [0.665–0.771]	<0.0001	28.7 [25.6–37.0]	89.8 [85.3–93.0]	59.7	70.4	68.6
HBV infection, n (%)
Yes (n = 183)	0.720 [0.672–0.768]	<0.0001	28.4 [22.4–35.3]	89.8 [85.3– 93.0]	67.5	62.6	63.5
No (n = 55)	0.754 [0.684–0.824]	<0.0001	38.2 [26.5–51.4]	89.8 [85.3– 93.0]	45.7	86.6	80.3
Metastasis, n (%)
Yes (n = 39)	0.719 [0.635–0.803]	<0.0001	33.3 [20.6– 49.0]	89.8 [85.3– 93.0]	34.2	89.4	82.0
No (n = 205)	0.727 [0.681–0.7730]	<0.0001	30.2 [24.4– 36.9]	89.8 [85.3– 93.0]	71.3	60.5	62.6

Note:

Cut off: 0.351 was determined by the 90% percentile of Nanchang NC. HCCs, hepatocellular carcinoma patients; NC, normal control.